BIENAIME JEAN JACQUES purchased $10K of KROS
BIENAIME JEAN JACQUES purchased 1,000 shares of Keros Therapeutics, Inc. (KROS) at $10.19 on 2026-06-15 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the director’s open-market purchase details (shares, price, date) and that it was executed under a pre-arranged 10b5-1 plan.
Market read
Insider buying can slightly improve sentiment, but the disclosed size and 10b5-1 structure suggest limited trading impact absent other catalysts.
What to watch
Traders may want to check for any concurrent sales by the same insider or other insiders, and whether there is any upcoming company-specific catalyst (trial readouts, financing, partnerships) not mentioned here.
Background
The article is an SEC Form 4 insider transaction disclosure for Keros Therapeutics, Inc.
Ticker impact
Keros Therapeutics director Bienaime Jean Jacques bought 1,000 shares at $10.19 on 2026-06-15 under a pre-arranged 10b5-1 plan.
Limited near-term impact; any effect is likely sentiment-only unless followed by larger transactions or fundamental news.
The filing is a routine insider buy (small dollar value) and explicitly tied to a pre-arranged 10b5-1 plan, reducing signal strength.
Market effects
No sector-level read-through; this is company-specific insider activity.
None indicated.
None indicated.
Counterpoint
Because the buy is under a pre-arranged 10b5-1 plan and is small ($10.2k), it may reflect scheduled liquidity rather than a strong bullish view.
Key entities
- issuerKeros Therapeutics, Inc.
Subject of the Form 4 insider transaction; director Bienaime Jean Jacques purchased 1,000 shares at $10.19 on 2026-06-15.
- insiderBIENAIME JEAN JACQUES
Director who reported the purchase; holdings after transaction: 17,592 shares.